Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

NCT04303130 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Camrelizumab

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]